Establishment of novel therapy for hepatitis C by double DDS drugs
| Project/Area Number |
22500410
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biological material science
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | ナノバイオロジー / ナノメディスン / DDS / ナノ粒子 / Ｃ型肝炎 / リバビリン / C型肝炎 / ポリ乳酸 |
|---|
| Research Abstract |
Novel drug carrier for ribavirin was developed for treatment of chronic hepatitis C. Polymeric nanoparticles encapsulating ribavirin were prepared fromarabinogalactan-poly(L-lysine) conjugates and poly(lactic acid). Ribavirin was specifically accumulated in the liver of mice and the amount of ribavirin was gradually decreased. Thus, it is expected that the nanoparticles are useful for treatment of chronic hepatitis C.
|
Report
(4 results)
Research Products
(33 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Therapeutic effect of lecithinized superoxide dismutase (PC-SOD) on bleomycin-induced pulmonary fibrosis.2010
Author(s)
Tanaka KI., Ishihara T., Azuma A., Kudoh S., Ebina M., Nukiwa T., Sugiyama Y., Tasaka Y., Namba T., Ishihara T., Sato K., Mizushima Y., Mizushima T.
-
Journal Title
Am J Physiol Lung Cell Mol Physiol.
Volume: 298
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] DDS材料2010
Author(s)
石原務
Organizer
第27回医用高分子研究会講座
Place of Presentation
東京
Year and Date
2010-11-18
Related Report
-
-
-
-
-
-
-
